InvestorsHub Logo
Followers 61
Posts 11577
Boards Moderated 0
Alias Born 07/16/2006

Re: None

Thursday, 11/01/2018 9:57:06 PM

Thursday, November 01, 2018 9:57:06 PM

Post# of 20689
Teva

Formulary access for 40 milligram Copaxone remains stable, around 90% nationally.

And Copaxone continues to be a market leader with Q3 TRx exit share of 22.7% of the MS market.

Of the 40 milligram glatiramer segment, Copaxone (Teva) 40 milligram total market share was approximately 77% versus generic (Mylan, Sandoz)40 milligram at approximately 23%.